Europe Pharmaceutical CDMO for Formulations Market Size is USD 15.25 Billion by 2026

Europe Pharmaceutical CDMO for Formulations Market (By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Others; By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology (Diabetes, Hormonal Therapy); By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Others) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 602 | Published : 11 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 14.17 Bn

Forecast Year,

USD 29.48 Bn

CAGR, 2026 - 2035

7.60%

Report Coverage

Europe

Download Databook

The Europe pharmaceutical CDMO for formulations market size was estimated at USD 14.17 billion in 2025 and is projected to be worth around USD 29.48 billion by 2035, is expanding at a CAGR of 7.60% from 2026 to 2035. Due to increasing outsourcing by pharmaceutical and biotech companies, strong healthcare infrastructure, skilled professionals, and rising demand for biologics, injectables, and personalised medicines are supporting market expansion.

Europe Pharmaceutical CDMO for Formulations Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 14.17 Billion
Market Size in 2026	USD 15.25 Billion
Market Size by 2035	USD 29.48 Billion
CAGR 2026 to 2035	7.60%
Base Year	2025
Forecast Period	2026 to 2035

It includes higher investments in advanced drug delivery systems, biologics , and flexible manufacturing solutions, countries such as Germany, France and Switzerland are major growth centres because of strong research activities and supportive regulations.

Technologies like automation, AI- based manufacturing, continuous production, and digital quality monitoring are improving efficiency and product quality, these innovations are helping European CDMOs, reduce costs, meet regulatory standards.

Segments	Shares (%)
Oral Solids	34%
Oral Liquids	11%
Injectables	26%
Topicals	9%
Inhalation Products	8%
Transdermal and Patches	7%
Others	5%

Oral Solids - The oral solids segment dominated the market with a share of 34% in 2025, due to high demand for tablets and capsules, patient convenience, cost- effective manufacturing, increasing outsourcing of large- scale drug production.
Oral Liquids - The oral liquids are rapidly growing with a market share of 11%, due to growing paediatric and geriatric demand, easier swallowing, flexible dosing, and raising production of syrups and suspensions
Injectables - The injectables segment held a 26% market share in 2025 and is expected to grow at a steady rate, due to rising biologics production, increasing chronic diseases treatments, faster drug action, and strong demand for sterile manufacturing services.

Segments	Shares (%)
Oncology	31%
Cardiology	18%
Central Nervous System	17%
Gastroenterology	11%
Infectious Diseases	13%
Endocrinology (Diabetes, Hormonal Therapy)	10%

Oncology - The oncology segment dominated the market with a share of 31% in 2025, due to increasing cancer prevalence, rising biologics development, and greater outsourcing of complex oncology drug manufacturing and formulation services.
Cardiology - The cardiology segment held a 18% market share in 2025 and is expected to grow at a steady rate, due to rising cardiovascular disease cases, increasing demand for chronic medications, and growing outsourcing of large- scale drug manufacturing services.
Central Nervous System - The central nervous system are rapidly growing with a market share of 17%, due to teaching neurological disorders, rising CNS drug development, and growing outsourcing of specialised formulation manufacturing services.

Segments	Shares (%)
Pharmaceutical Companies	52%
Biopharmaceutical Companies	38%
Others	10%

Pharmaceutical Companies - The pharmaceutical companies segment dominated the market with a share of 52% in 2025, due to rising outsourcing needs, cost reduction strategies, faster drug development, and increasing to month for a specialised formulation manufacturing services.
Biopharmaceutical Companies - The biopharmaceutical companies segment held a 38% market share in 2025 and is expected to grow at a steady rate, due to rising biologics development, increasing demand for specialised manufacturing, and growing outsourcing of complex formulation and production processes.
Others - The others are rapidly growing with a market share of 10%, due to growing demand for research institutes, speciality healthcare firms, and small companies requiring flexible formulation and manufacturing support services.

Top Companies in the Europe Pharmaceutical CDMO for Formulations Market

Lonza
Thermo Fisher Scientific, Inc.
Recipharm AB
Laboratory Corporation of America Holdings (LabCorp)
Catalent, Inc.
WuXi AppTec, Inc.
Piramal Pharma Solutions
Siegfried Holding AG
CordenPharma International
Cambrex Corporation
Bushu Pharmaceuticals Ltd.
Nipro Corporation
EuroAPI
Hovione
Curia

Segments Covered in the Report

By Dosage Form

Oral Solids
Oral Liquids
Injectables
Topicals
Inhalation Products
Transdermal And Patches
Others

By Therapeutic Area

Oncology
Cardiology
Central Nervous System
Gastroenterology
Infectious Diseases
Endocrinology (Diabetes, Hormonal Therapy)

By End User

Pharmaceutical Companies
Biopharmaceutical Companies
Others

List of Tables & Figures

List of Tables

Table 1: Europe Pharmaceutical CDMO for Formulations Market Size, by Dosage Form, 2025-2035 (USD Billion)
Table 2: Europe Pharmaceutical CDMO for Formulations Market Size, by Oral Solids, 2025-2035 (USD Billion)
Table 3: Europe Pharmaceutical CDMO for Formulations Market Size, by Oral Liquids, 2025-2035 (USD Billion)
Table 4: Europe Pharmaceutical CDMO for Formulations Market Size, by Injectables, 2025-2035 (USD Billion)
Table 5: Europe Pharmaceutical CDMO for Formulations Market Size, by Topicals, 2025-2035 (USD Billion)
Table 6: Europe Pharmaceutical CDMO for Formulations Market Size, by Inhalation Products, 2025-2035 (USD Billion)
Table 7: Europe Pharmaceutical CDMO for Formulations Market Size, by Transdermal & Patches, 2025-2035 (USD Billion)
Table 8: Europe Pharmaceutical CDMO for Formulations Market Size, by Others (Dosage Form), 2025-2035 (USD Billion)
Table 9: Europe Pharmaceutical CDMO for Formulations Market Size, by Therapeutic Area, 2025-2035 (USD Billion)
Table 10: Europe Pharmaceutical CDMO for Formulations Market Size, by Oncology, 2025-2035 (USD Billion)
Table 11: Europe Pharmaceutical CDMO for Formulations Market Size, by Cardiology, 2025-2035 (USD Billion)
Table 12: Europe Pharmaceutical CDMO for Formulations Market Size, by Central Nervous System, 2025-2035 (USD Billion)
Table 13: Europe Pharmaceutical CDMO for Formulations Market Size, by Gastroenterology, 2025-2035 (USD Billion)
Table 14: Europe Pharmaceutical CDMO for Formulations Market Size, by Infectious Diseases, 2025-2035 (USD Billion)
Table 15: Europe Pharmaceutical CDMO for Formulations Market Size, by Endocrinology (Diabetes, Hormonal Therapy), 2025-2035 (USD Billion)
Table 16: Europe Pharmaceutical CDMO for Formulations Market Size, by End User, 2025-2035 (USD Billion)
Table 17: Europe Pharmaceutical CDMO for Formulations Market Size, by Pharmaceutical Companies, 2025-2035 (USD Billion)
Table 18: Europe Pharmaceutical CDMO for Formulations Market Size, by Biopharmaceutical Companies, 2025-2035 (USD Billion)
Table 19: Europe Pharmaceutical CDMO for Formulations Market Size, by Others (End User), 2025-2035 (USD Billion)
Table 20: Germany Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 21: France Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 22: UK Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 23: Italy Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 24: Europe Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Table 25: Europe Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Table 26: Europe Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)

List of Figures

Figure 1: Europe Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Figure 2: Europe Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Figure 3: Europe Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)
Figure 4: Europe Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 5: Europe Oral Solids Market Forecast, 2025-2035 (USD Billion)
Figure 6: Europe Oral Liquids Market Forecast, 2025-2035 (USD Billion)
Figure 7: Europe Injectables Market Forecast, 2025-2035 (USD Billion)
Figure 8: Europe Topicals Market Forecast, 2025-2035 (USD Billion)
Figure 9: Europe Inhalation Products Market Forecast, 2025-2035 (USD Billion)
Figure 10: Europe Transdermal & Patches Market Forecast, 2025-2035 (USD Billion)
Figure 11: Europe Oncology Market Forecast, 2025-2035 (USD Billion)
Figure 12: Europe Cardiology Market Forecast, 2025-2035 (USD Billion)
Figure 13: Europe Central Nervous System Market Forecast, 2025-2035 (USD Billion)
Figure 14: Europe Gastroenterology Market Forecast, 2025-2035 (USD Billion)
Figure 15: Europe Infectious Diseases Market Forecast, 2025-2035 (USD Billion)
Figure 16: Europe Endocrinology Market Forecast, 2025-2035 (USD Billion)
Figure 17: Europe Pharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 18: Europe Biopharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 19: Germany Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 20: France Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 21: UK Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 22: Italy Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)

Research Methodology

Related Databooks

March 2026